- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02668484
REpositionable Versus BallOOn-expandable Prosthesis for Trans-catheter Aortic Valve Implantation (REBOOT)
Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Important improvements in aortic valve prostheses technology has been made aiming comparable performance of these prosthesis to surgical valve ones.
The experience with the early generation of aortic valve prostheses revealed some important differences regarding the incidence of paravalvular leakage, need for pacemaker or valve thrombosis among them. Currently the new generations of valve prostheses such as Sapien 3 balloon-expandable valve and Lotus, repositionable valve are the most frequently used devices. There are registry data about the clinical performance of these valve types but a randomized comparison is missing.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Symptomatic aortic valve disease in need of valve replacement
- Heart team (including at least a cardiac surgeon and an interventional cardiologist) agrees on the eligibility that trans-femoral TAVI is appropriate.
- Study patient is an adult of legal consent age.
- Study patient has provided written informed consent to participate in the study
Exclusion Criteria:
- Life expectancy < 12 months due to co-morbid conditions.
- Native aortic valve annulus size and morphology not suitable for Lotus or Sapien prosthesis implantation
- Preexisting bioprosthetic valve or ring in aortic valve position.
- Pre-existing pacemaker or ICD/CRT.
- Cardiogenic shock or hemodynamic instability.
- History of active endocarditis
- Contraindications for a trans-femoral access.
- Severe left ventricular dysfunction with LVEF <30%.
- Severe mitral valve insufficiency.
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
- Patients actively participating in another drug or device investigational study and have not yet completed the primary endpoint follow-up period.
- Patients suffering from dementia.
- Pregnant or nursing women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: repositionable valve prosthesis
Lotus
|
repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
Other Names:
|
Active Comparator: balloon-expandable valve prosthesis
Sapien
|
balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of new permanent pacemaker implantation
Time Frame: 30 days
|
implantation of PM
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence of any prosthesis regurgitation
Time Frame: 30 days
|
prosthesis regurgitation in echocardiography
|
30 days
|
Incidence of any conduction abnormalities
Time Frame: 30 days
|
conduction abnormalities on rest ECG
|
30 days
|
Device success rate according to VARC-2 definition
Time Frame: 30 days
|
combined endpoint
|
30 days
|
Mortality rate
Time Frame: 30 days
|
all-cause death
|
30 days
|
Mortality rate
Time Frame: 1 year
|
all-cause death
|
1 year
|
Mortality rate
Time Frame: 2 years
|
all-cause death
|
2 years
|
incidence of early safety parameters according to VARC-2 definitions
Time Frame: 30 days
|
combined endpoint
|
30 days
|
incidence of combined efficacy according to VARC-2 definitions
Time Frame: 1 year
|
combined endpoint
|
1 year
|
incidence of combined efficacy according to VARC-2 definitions
Time Frame: 2 years
|
combined endpoint
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julinda Mehilli, MD, Munich University Clinic, Ludwig-Maximilians University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GEMucS001-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Disease
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaTerminatedAortic Regurgitation | Aortic Valve Insufficiency | Regurgitation, Aortic Valve | Aortic Valve | Aortic IncompetenceKorea, Republic of
-
Genesis Medtech CorporationRecruiting
-
Assistance Publique Hopitaux De MarseilleSuspendedAortic Valve Regurgitation AcquiredFrance
-
The Cleveland ClinicRecruitingAortic Stenosis | Aortic Regurgitation | Valve Heart DiseaseUnited States
-
Na Homolce HospitalCentre of Cardiovascular and Transplantation Surgery, Czech Republic; St. Anne... and other collaboratorsRecruitingAortic Valve RegurgitationSerbia, Czechia, Belgium
-
Oslo University HospitalCompletedCoronary Artery Disease. | Aortic Valve Stenosis. | Aortic Valve Regurgitation.Norway
-
Han Yaling, MDRecruitingCardiac Rehabilitation | Valve Disease, AorticChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingAortic Regurgitation | Transcatheter Aortic Valve ReplacementChina
-
Fondazione Policlinico Universitario Agostino Gemelli...Enrolling by invitationAortic Valve Stenosis | Heart Valve Diseases | Aortic Regurgitation | Aortic Valve Insufficiency | Aortic Stenosis, Severe | Regurgitation, Aortic | Stenoses, Aortic | Coronary; Obstruction | Valve Disease, AorticItaly
-
UMC UtrechtTerminatedPeriprosthetic Aortic Valve Regurgitation After TAVINetherlands
Clinical Trials on repositionable valve prosthesis
-
Tomsk National Research Medical Center of the Russian...Active, not recruitingDegenerative Mitral Valve DiseaseRussian Federation
-
Corcym S.r.lTerminatedAortic Valve ReplacementBelgium, Germany, Netherlands, France, Austria, Poland, Switzerland, United Kingdom
-
Edwards LifesciencesPacific Clinical Research GroupCompleted
-
University of AarhusAarhus University Hospital; Abbott Medical Devices; LivaNova; Raimond and Dagmar... and other collaboratorsCompleted
-
Venus MedTech (HangZhou) Inc.UnknownAortic Valve Stenosis | Aortic Valve CalcificationChina
-
Haukeland University HospitalCompletedHypertension | Aortic Stenosis
-
Edwards LifesciencesCompletedSevere Aortic StenosisSpain, Italy, Canada, Belgium, Greece, Germany, Austria, United Kingdom, Finland, Denmark, France, Switzerland, Israel, Poland, South Africa, Czechia, Netherlands, Norway
-
Meshalkin Research Institute of Pathology of CirculationUnknownAortic Insufficiency | Ascending Aorta AneurismRussian Federation
-
Edwards LifesciencesCompletedSymptomatic Severe Aortic StenosisUnited States, Canada
-
VA Eastern Colorado Health Care SystemUnited States Department of DefenseCompletedWounds and Injuries | Amputation, Traumatic | Traumatic Amputation of Lower ExtremityUnited States